Intel stock spikes after report of possible US government stake
HealthSouth Corp (NYSE:EHC) stock soared to a 52-week high, reaching a price level of $121.29 USD, with analysts setting price targets ranging from $122 to $140. According to InvestingPro analysis, the stock currently appears overvalued based on its Fair Value assessment. This peak reflects a significant uptrend for the healthcare services provider, marking a notable milestone in the company’s stock performance over the past year. Investors have shown increased confidence in HealthSouth Corp, as evidenced by the impressive 42.45% total return over the past year. The company maintains a "GREAT" financial health score of 3.36 out of 5, supported by strong revenue growth of 11.21% and a healthy gross profit margin of 42.05%. This surge in stock price underscores the company’s robust financial health and the positive sentiment surrounding its growth prospects in the healthcare industry. For deeper insights into EHC’s valuation and growth potential, including 12 additional ProTips and comprehensive financial metrics, explore the full research report available on InvestingPro.
In other recent news, Encompass Health Corporation reported first-quarter 2025 earnings that exceeded analysts’ expectations, with an earnings per share (EPS) of $1.37 compared to a forecast of $1.20. Revenue also surpassed projections, reaching $1.46 billion against an expected $1.43 billion. Following this strong performance, Encompass Health raised its full-year guidance, anticipating higher net operating revenue and EPS. Mizuho (NYSE:MFG) Securities and RBC Capital Markets responded positively to these results, with Mizuho raising its price target for the company to $130 and maintaining an Outperform rating, while RBC increased its target to $125, also keeping an Outperform rating. These adjustments reflect confidence in Encompass Health’s robust start to the year and its potential for continued growth.
Additionally, Encompass Health declared a quarterly cash dividend of $0.17 per share, reinforcing its financial stability and commitment to shareholder value. Shareholders recently approved the company’s 2025 Omnibus Performance Incentive Plan, aligning executive compensation with company performance. The approval was part of an annual meeting where other key proposals, including board member elections and auditor ratification, were also passed. These developments highlight Encompass Health’s strategic focus on growth and shareholder engagement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.